Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CAR-T cell therapies - TxCell

Drug Profile

Research programme: CAR-T cell therapies - TxCell

Alternative Names: CAR engineered CD4+ Treg cells - TxCell; CD4+ CD25+ CD45RA+ Tregs; CD45RA+ Tregs; ENTrIA; ENTX-BP; ENTX-LN

Latest Information Update: 24 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Ospedale San Raffaele; TxCell; University of Lubeck; Weizmann Institute of Science
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bullous pemphigoid
  • Research Inflammatory bowel diseases; Lupus nephritis; Rheumatoid arthritis

Most Recent Events

  • 24 Oct 2018 Early research in Inflammatory bowel disease in France (Parenteral)
  • 24 Oct 2018 Early research in Rheumatoid arthritis in France (Parenteral)
  • 01 Oct 2018 TxCell has been acquired by Sangamo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top